case_images: PMC7231770_01
case_images: Case 1. (A) Before and after OCT images of the patient after 3 intravitreal aflibercept injections every 4 weeks. (B) Before and after OCT image 1 month after 1 intravitreal brolucizumab injection.
case_images: IMCRJ-13-145-g0001.jpg
case_images: PMC7231770_06_IMCRJ-13-145-g0001.jpg
case_images: F0001
case_images: OS. OCT showed slightly improved central IRF, and the CMT improved by 17 microns compared to pre-brolucizumab baseline (Figure 6B, Table 1).
case_images: PMC7231770_02
case_images: Case 1. (A) Before and after OCT images of the patient after 3 intravitreal aflibercept injections every 4 weeks. (B) Before and after OCT image 1 month after 1 intravitreal brolucizumab injection.
case_images: IMCRJ-13-145-g0001.jpg
case_images: PMC7231770_06_IMCRJ-13-145-g0001.jpg
case_images: F0001
case_images: OS. OCT showed slightly improved central IRF, and the CMT improved by 17 microns compared to pre-brolucizumab baseline (Figure 6B, Table 1).
case_images: Case 2. (A) Before and after OCT images of the patient after 4 intravitreal aflibercept injections every 4 weeks. (B) Before and after OCT image 1 month after 1 intravitreal brolucizumab injection.
case_images: IMCRJ-13-145-g0002.jpg
case_images: PMC7231770_02_IMCRJ-13-145-g0002.jpg
case_images: F0002
case_images: Repeat fluorescein and indocyanine green angiograms showed persistent occult CNV and leakage on OCT (Figure 2A). OD. OCT showed improved SRF, and the CMT decreased by 14 microns from the pre-brolucizumab baseline (Figure 2B, Table 1).
case_images: PMC7231770_03
case_images: Case 1. (A) Before and after OCT images of the patient after 3 intravitreal aflibercept injections every 4 weeks. (B) Before and after OCT image 1 month after 1 intravitreal brolucizumab injection.
case_images: IMCRJ-13-145-g0001.jpg
case_images: PMC7231770_06_IMCRJ-13-145-g0001.jpg
case_images: F0001
case_images: OS. OCT showed slightly improved central IRF, and the CMT improved by 17 microns compared to pre-brolucizumab baseline (Figure 6B, Table 1).
case_images: Case 3. (A) Before and after OCT images of the patient after 3 intravitreal aflibercept injections every 4 weeks. (B) Before and after OCT image 1 month after 1 intravitreal brolucizumab injection.
case_images: IMCRJ-13-145-g0003.jpg
case_images: PMC7231770_03_IMCRJ-13-145-g0003.jpg
case_images: F0003
case_images: However, after 5 treatments with aflibercept, OCT showed increased edema, and the patient was started on brolucizumab (Figure 3A). OS. OCT showed improved IRF, and the APT decreased by 15 microns from the pre-brolucizumab baseline (Figure 3B, Table 1).
case_images: PMC7231770_04
case_images: Case 1. (A) Before and after OCT images of the patient after 3 intravitreal aflibercept injections every 4 weeks. (B) Before and after OCT image 1 month after 1 intravitreal brolucizumab injection.
case_images: IMCRJ-13-145-g0001.jpg
case_images: PMC7231770_06_IMCRJ-13-145-g0001.jpg
case_images: F0001
case_images: OS. OCT showed slightly improved central IRF, and the CMT improved by 17 microns compared to pre-brolucizumab baseline (Figure 6B, Table 1).
case_images: Case 4. (A) Before and after OCT images of the patient after 3 intravitreal bevacizumab injections every 2-3 months. (B) Before and after OCT images 1 month after 1 intravitreal brolucizumab injection.
case_images: IMCRJ-13-145-g0004.jpg
case_images: PMC7231770_04_IMCRJ-13-145-g0004.jpg
case_images: F0004
case_images: On return, his BCVA was 20/40 OD; however, fluorescein/indocyanine green angiograms and OCT showed progressive fibrovascular changes along with IRF (Figure 4A). OD. OCT showed significantly improved IRF, and the CMT decreased by 57 microns compared to pre-brolucizumab baseline (Figure 4B, Table 1).
case_images: PMC7231770_05
case_images: Case 1. (A) Before and after OCT images of the patient after 3 intravitreal aflibercept injections every 4 weeks. (B) Before and after OCT image 1 month after 1 intravitreal brolucizumab injection.
case_images: IMCRJ-13-145-g0001.jpg
case_images: PMC7231770_06_IMCRJ-13-145-g0001.jpg
case_images: F0001
case_images: OS. OCT showed slightly improved central IRF, and the CMT improved by 17 microns compared to pre-brolucizumab baseline (Figure 6B, Table 1).
case_images: Case 5. (A) Before and after OCT images of the patient after 4 intravitreal aflibercept injections every 4 weeks. (B) Before and after OCT images 1 month after 1 intravitreal brolucizumab injection.
case_images: IMCRJ-13-145-g0005.jpg
case_images: PMC7231770_05_IMCRJ-13-145-g0005.jpg
case_images: F0005
case_images: OS. OCT showed no improvement in macular edema over the last 3 months and irregular thickening of the choroid (Figure 5A), as well as some focal hyperfluorescence with late cystoid macular edema on fluorescein angiogram (not shown). OS. OCT showed slightly improved IRF, and the CMT decreased by 18 microns compared to pre-brolucizumab baseline (Figure 5B, Table 1).
case_images: PMC7231770_06
case_images: Case 1. (A) Before and after OCT images of the patient after 3 intravitreal aflibercept injections every 4 weeks. (B) Before and after OCT image 1 month after 1 intravitreal brolucizumab injection.
case_images: IMCRJ-13-145-g0001.jpg
case_images: PMC7231770_06_IMCRJ-13-145-g0001.jpg
case_images: F0001
case_images: OS. OCT showed slightly improved central IRF, and the CMT improved by 17 microns compared to pre-brolucizumab baseline (Figure 6B, Table 1).
case_images: Case 6. (A) Before and after OCT images of the patient after 1 intravitreal aflibercept injection. (B) Before and after OCT images 1 month after 1 intravitreal brolucizumab injection.
case_images: IMCRJ-13-145-g0006.jpg
case_images: PMC7231770_06_IMCRJ-13-145-g0006.jpg
case_images: F0006
case_images: OS on monthly aflibercept intravitreal injections for 4 treatments OU until recently when the patient's VA OS dropped to 20/100. OCT showed increased macular thickness, appreciated on OCT difference map (Figure 6A). OS. OCT showed slightly improved central IRF, and the CMT improved by 17 microns compared to pre-brolucizumab baseline (Figure 6B, Table 1).